Andreana N. Holowatyj, PhD, MS, Discusses Focal Questions Regarding Colorectal Cancer Disparities

Video

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork about the focal questions from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on disparities in early-onset colorectal cancer.

Transcription:

We sought to tackle the loaded question to understand what biological factors may be contributing to disparities in the early-onset colorectal cancer burden. To put things into perspective, overall about 1 in every 10 colorectal cancer cases is diagnosed prior to age 50. There’s been a challenge to date in accruing sufficient cases or data to be able to explore this timely and important research question as to differences within the population of early-onset colorectal cancer, particularly the molecular features. It was a really unique opportunity to leverage the resource of the AACR Project GENIE [Genomic Evidence Neoplasia Information Exchange] consortium that included both clinical-grade targeted sequencing data, and clinical demographic data on cases with a pathologically confirmed colorectal cancer diagnosis from 12 institutions worldwide, which was [a] prime opportunity to answer this research question with over 6000 colorectal cancer cases included in our study.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content